Purpose: To evaluate signs and character of carbohydrate metabolism regulation in patients with BA.Material and methods: In 77 patients with BA, having basis treatment with beta2-AG in doses 936±92,9 mkg and sGC in doses to 54,4±3,4 mg and in 10 patients with BA, having basal treatment beta2-AG in dose 587,5±124,7 mkg there was investigated subcutaneous insulin test by Hirnsworth and Kerr (1939) and glucose-tolerability test by S.Fajans with calculation of coefficients: hypoglycemic (hGC), postglycemic (pGC). Transport of glucose was investigated in vitro on the erythrocyte model by Bulatova N. (1993) with calculations of glucose excretory (GE) and glucose absorption (GA). Results: The level of hGC exceeding 1,6±0,1 was noted in 58,5±7,7% of persons treated with beta2-AG in combination with sGC against 4,9±1,4% during treatment only with beta2-AG. pGC more lower than 1,3±0,1 was noted in 64,3±7,4 against 4,8±2,3 % in persons and absence of postglycemic phase – in 58,8±11,9 and 5,9±2,4% of persons, respectively. The reduced receptor sensitivity to insulin manifesting by glycemia change less than -24±0,01% was noted in 60% of persons in combined therapy against 10±5,5% of persons treated only with beta2-AG. There was determined fact of disorders of membrane transport in patients treated only with beta2-AG and beta2-AG in combination with sGC with tendency to prevail of the processes of GA over GE (ΔGA-GE+0,03±0,18 and +0,08±0,13 against Δ= -0,12±0,1 mmol/l in health controls). Conclusion: Thus, sGC in combination with beta2-agonists accumulate hyperglycemic effects and result in more marked disorders at the cellular-receptor levels of metabolism regulation.